HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) is expanding its international footprint as interest grows in its device-based dermatology treatments, highlighted by new commercial momentum in Mexico following a major regional medical conference.
The company said it participated in the 2025 Ibero-Latin American Congress of Dermatology, known as TeraCILAD, held November 19–22, where it presented its XTRAC excimer laser and TheraclearX acne therapy system. STRATA reported that more than 12 new recurring TheraclearX accounts are expected to be active in Mexico by the end of 2025, signaling increasing adoption among dermatologists seeking non-drug treatment options.
At the biennial conference, organized by the Latin American College of Dermatology, STRATA showcased XTRAC, a targeted ultraviolet B excimer laser used to treat psoriasis, vitiligo, and other inflammatory skin disorders, alongside TheraclearX, a photopneumatic system designed to treat mild to moderate acne. Both systems are positioned as in-office therapies that avoid systemic medications.
Clinical interest was reinforced during presentations by regional and global dermatology leaders. Dr. Melissa Lomeli, the first TheraclearX user in Mexico, shared early clinical experience with the acne system, describing rapid patient response following short treatment sessions. Dr. Henry Lim, an international authority on autoimmune and inflammatory skin diseases, presented data on XTRAC’s use in vitiligo, psoriasis, and atopic dermatitis.
Company executives said the engagement at TeraCILAD reflected a broader shift in dermatology toward device-based therapies that can be integrated into routine practice. Chief Operating Officer Shmuel Gov said physicians are increasingly focused on effective, non-systemic options that deliver measurable outcomes without adding medication burden.
STRATA has already begun placing TheraclearX systems commercially in Mexico, with management pointing to the recurring nature of treatments as a driver of sustainable revenue. Chief Executive Officer Dolev Rafaeli said that while it is still early to quantify the full commercial impact of each placement, experience with XTRAC in other international markets shows that mature clinics can generate more than $30,000.00 in annual revenue per location.
As STRATA continues to build awareness across Latin America, the company is positioning its technology portfolio as both a clinical solution for physicians and a long-term growth engine in markets where demand for advanced, non-pharmaceutical dermatology care is rising.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.